Nonviral delivery vehicles for use in short hairpin RNA-based cancer therapies - PubMed (original) (raw)
Review
Nonviral delivery vehicles for use in short hairpin RNA-based cancer therapies
John S Vorhies et al. Expert Rev Anticancer Ther. 2007 Mar.
Abstract
The use of DNA vector-based short hairpin (sh)RNA for RNA interference shows promise as a precise means for the disruption of gene expression to achieve a therapeutic effect. The in vivo usage of shRNA therapeutics in cancer is limited by obstacles related to effective delivery into the nuclei of target cancer cells. Nonviral delivery vehicles that are relevant for shRNA delivery into humans belong to a group of substances about which significant preclinical data has been amassed to show an acceptable safety profile, resistance to immune defenses and good transfection efficiency. Here, we review the most promising current nonviral gene delivery vehicles with a focus on their potential use in cancer shRNA therapeutics.
Similar articles
- Synthetic vs. natural/biodegradable polymers for delivery of shRNA-based cancer therapies.
Vorhies JS, Nemunaitis JJ. Vorhies JS, et al. Methods Mol Biol. 2009;480:11-29. doi: 10.1007/978-1-59745-429-2_2. Methods Mol Biol. 2009. PMID: 19085121 Review. - Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.
Takahashi Y, Nishikawa M, Takakura Y. Takahashi Y, et al. Adv Drug Deliv Rev. 2009 Jul 25;61(9):760-6. doi: 10.1016/j.addr.2009.04.006. Epub 2009 Apr 20. Adv Drug Deliv Rev. 2009. PMID: 19386274 Review. - Advances in the development of siRNA-based therapeutics for cancer.
Shen Y. Shen Y. IDrugs. 2008 Aug;11(8):572-8. IDrugs. 2008. PMID: 18683092 Review. - Strategies for short hairpin RNA delivery in cancer gene therapy.
Wang SL, Yao HH, Qin ZH. Wang SL, et al. Expert Opin Biol Ther. 2009 Nov;9(11):1357-68. doi: 10.1517/14712590903236843. Expert Opin Biol Ther. 2009. PMID: 19761417 Review. - Nonviral in vivo delivery of therapeutic small interfering RNAs.
Aigner A. Aigner A. Curr Opin Mol Ther. 2007 Aug;9(4):345-52. Curr Opin Mol Ther. 2007. PMID: 17694447 Review.
Cited by
- Nonviral delivery of synthetic siRNAs in vivo.
Akhtar S, Benter IF. Akhtar S, et al. J Clin Invest. 2007 Dec;117(12):3623-32. doi: 10.1172/JCI33494. J Clin Invest. 2007. PMID: 18060020 Free PMC article. Review. - Ethical perspectives on RNA interference therapeutics.
Ebbesen M, Jensen TG, Andersen S, Pedersen FS. Ebbesen M, et al. Int J Med Sci. 2008 Jun 25;5(3):159-68. doi: 10.7150/ijms.5.159. Int J Med Sci. 2008. PMID: 18612370 Free PMC article. - Targeting hypoxia-inducible factor-1alpha with Tf-PEI-shRNA complex via transferrin receptor-mediated endocytosis inhibits melanoma growth.
Liu Y, Tao J, Li Y, Yang J, Yu Y, Wang M, Xu X, Huang C, Huang W, Dong J, Li L, Liu J, Shen G, Tu Y. Liu Y, et al. Mol Ther. 2009 Feb;17(2):269-77. doi: 10.1038/mt.2008.266. Epub 2008 Dec 9. Mol Ther. 2009. PMID: 19066596 Free PMC article. - Use of liposomes as drug delivery vehicles for treatment of melanoma.
Tran MA, Watts RJ, Robertson GP. Tran MA, et al. Pigment Cell Melanoma Res. 2009 Aug;22(4):388-99. doi: 10.1111/j.1755-148X.2009.00581.x. Epub 2009 May 22. Pigment Cell Melanoma Res. 2009. PMID: 19493316 Free PMC article. Review. - MicroRNAs as therapeutic targets in human cancers.
Shah MY, Calin GA. Shah MY, et al. Wiley Interdiscip Rev RNA. 2014 Jul-Aug;5(4):537-48. doi: 10.1002/wrna.1229. Epub 2014 Mar 28. Wiley Interdiscip Rev RNA. 2014. PMID: 24687772 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical